Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SB17170 in Idiopathic Pulmonary Fibrosis: NCT06747923 Clinical Landscape Report 2026
28 September 2026
NCT06747923 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ORT-247 in Amyotrophic Lateral Sclerosis: NCT06769620 Clinical Landscape Report 2026
28 September 2026
NCT06769620 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VGN-R13 in Amyotrophic Lateral Sclerosis: NCT06849609 Clinical Landscape Report 2026
28 September 2026
NCT06849609 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
FHND1002 in Amyotrophic Lateral Sclerosis: NCT06782958 Clinical Landscape Report 2026
28 September 2026
NCT06782958 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Psilocybin in Pulmonary Disease, Chronic Obstructive: NCT06782724 Clinical Landscape Report 2026
28 September 2026
NCT06782724 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Levocarnitine in Amyotrophic Lateral Sclerosis: NCT06849115 Clinical Landscape Report 2026
28 September 2026
NCT06849115 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SHED-CM(U Factor) in Amyotrophic Lateral Sclerosis: NCT06889857 Clinical Landscape Report 2026
28 September 2026
NCT06889857 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![[18F]ACI-19626 in Alzheimer Disease: NCT06891716 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_14_36b6ffee12.jpg)
9 min read
[18F]ACI-19626 in Alzheimer Disease: NCT06891716 Clinical Landscape Report 2026
28 September 2026
NCT06891716 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tazbentetol in Amyotrophic Lateral Sclerosis: NCT06903286 Clinical Landscape Report 2026
28 September 2026
NCT06903286 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Kesonotide in Glioblastoma Multiforme: NCT06926075 Clinical Landscape Report 2026
28 September 2026
NCT06926075 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
STR-04 in Amyotrophic Lateral Sclerosis: NCT06910384 Clinical Landscape Report 2026
28 September 2026
NCT06910384 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CUE-102 in Recurrent Glioblastoma: NCT06917885 Clinical Landscape Report 2026
28 September 2026
NCT06917885 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.